Core Insights - Pacira BioSciences presented real-world evidence demonstrating the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for osteoarthritis patients at the AAOS 2026 Annual Meeting [1][2] Group 1: EXPAREL Findings - The first study indicated that patients receiving EXPAREL showed significant improvements in pain, opioid use, function, and length of stay after total knee arthroplasty compared to those receiving conventional bupivacaine and ropivacaine [1][3] - Patients treated with EXPAREL reported lower average pain scores (3.9 vs 4.9) and worst pain scores (5.9 vs 7.1) in the first five days post-surgery, with statistical significance (P<0.001) [3] - Patients receiving EXPAREL were discharged earlier (15.0 hours) compared to those receiving conventional local anesthetics (20.6 hours) [3] Group 2: ioveraº Findings - The second study showed that cryoneurolysis treatment with ioveraº resulted in long-term pain and functional improvements for up to 12 months, significantly exceeding the typical 4-6 months of relief from alternative intra-articular agents [1][3] - Data from 129 patients indicated that cryoneurolysis was associated with long-term reductions in pain and improved function (P<0.01) [3] Group 3: Innovations in Genicular Outcomes Registry (IGOR) - IGOR is a first-of-its-kind multicenter, prospective, longitudinal observational registry aimed at providing real-world evidence and insights into the patient journey for osteoarthritis treatment [2][11] - The registry collects comprehensive data on patient characteristics, clinical outcomes, and economic impacts, contributing to evidence-based preoperative pain management strategies [2][11] Group 4: Company Overview - Pacira BioSciences focuses on innovative, non-opioid pain therapies, with three commercial-stage products: EXPAREL, ZILRETTA, and ioveraº [4] - The company is advancing a pipeline of clinical-stage assets, including PCRX-201, a novel gene therapy for knee osteoarthritis currently in Phase 2 clinical development [4]

Core Insights - Pacira BioSciences, Inc. will report its third quarter financial results on November 6, 2025, after U.S. market close [1] - A live conference call and webcast will follow the financial results announcement at 4:30 p.m. ET [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3] - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]

Core Viewpoint - Pacira BioSciences, Inc. is set to report its second quarter financial results on August 5, 2025, and will host a live conference call and webcast following the release [1]. Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3]. - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3]. - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3]. - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control through cold temperature [3]. - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3].

Core Insights - Pacira BioSciences, Inc. is committed to delivering innovative, non-opioid pain therapies to transform patients' lives [2] - The company will participate in two upcoming healthcare conferences, providing opportunities for analysts to engage with its leadership [1][3] Company Overview - Pacira has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic approved for various postsurgical pain management applications [2] - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [2] - ioveraº, a handheld device for drug-free pain control using cold temperature [2] - The company is also developing PCRX-201, a novel gene therapy aimed at treating prevalent diseases like osteoarthritis [2]

Core Viewpoint - Pacira BioSciences, Inc. is set to report its first quarter financial results on May 8, 2025, and will host a live conference call following the release [1] Company Overview - Pacira specializes in innovative, non-opioid pain therapies aimed at transforming patient lives [3] - The company has three commercial-stage non-opioid treatments: - EXPAREL, a long-acting local analgesic for various postsurgical pain management applications [3] - ZILRETTA, an extended-release injection for osteoarthritis knee pain management [3] - ioveraº, a handheld device providing immediate, long-acting, drug-free pain control [3] - Pacira is also developing PCRX-201, a novel gene therapy targeting prevalent diseases like osteoarthritis [3]